{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-07-08",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Ongoing",
      "city": "El Paso",
      "state": "TX",
      "country": "United States",
      "classification": "Class II",
      "openfda": {},
      "product_type": "Drugs",
      "event_id": "95777",
      "recalling_firm": "MXBBB",
      "address_1": "1162 Tio Dink Cir",
      "address_2": "",
      "postal_code": "79907-1912",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Press Release",
      "distribution_pattern": "Product was sold via Amazon Marketplace.",
      "recall_number": "D-0166-2025",
      "product_description": "UMARY ACID HYALURONIC, 850 MG CAPLETS, 30-count bottle, UPC7502265120323",
      "product_quantity": "321 bottles",
      "reason_for_recall": "cGMP Deviations: the firm initiated a recall after notification from the distributor that product may be tainted with undeclared diclofenac and omeprazole, however there is no analytical data confirming that product distributed by the firm is tainted.",
      "recall_initiation_date": "20241114",
      "center_classification_date": "20241226",
      "report_date": "20250101",
      "code_info": "Lot#: 24183, Exp 07/01/28",
      "more_code_info": ""
    }
  ]
}